Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Online program aims to slash dementia risk with personalized lifestyle coaching

NCT ID NCT06748625

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This study tests an online program called Luci that helps people aged 50 to 75 adopt healthier habits to lower their risk of dementia. The program provides educational materials, tips, and a personal coach to guide participants in improving physical activity, diet, and mental engagement. Researchers want to see if the program leads to meaningful lifestyle changes over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Luci Coach-Assisted Intervention (behavioral program via web platform with coach support)
What this could lead to
If successful, this program could become an effective tool to help people reduce their risk of dementia through lifestyle changes.
What could go wrong
This is a behavioral intervention, so results depend on participants sticking with the program. The study measures lifestyle changes, not dementia itself, so it's unclear if these changes actually prevent cognitive decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 370 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * Aged between 50 and 75; * Proficient or native speakers in French or English; * Computer literate defined as being able to read mails and browse the Internet, and having access to a computer or tablet with an Internet connection; * Eligible in at least one of the 3 intervention domains, where eligibility is defined as follows: * Low cognitive engagement in cognitively stimulating activities, defined as a score ≤ 22 on the adapted Cognitive Activity Questionnaire; * Low level of physical activity defined as less than 150 minutes/week) of moderate to vigorous physical activity measured using the Godin- Shephard Leisure Time Physical Activity Questionnaire, and no medical contraindication to physical activity based on the Physical Readiness Questionnaire for Everyone (PAR-Q+); * Low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale, and no dietary restriction, severe allergy or intolerance or history of eating disorder. Exclusion Criteria : * Presence of a cognitive impairment as measured by the Creyos Dementia Assessment; * General anesthesia within the last 6 months; * Previous participation in the Luci program or in any validation studies related to the program; * Current participation in another study; * Unable to commit participation over the period of the study; * Being in the precontemplation stage of change; * High level of perceived stress; * Having received a diagnosis of : * Dementia or neurodegenerative disease (AD and other dementias); * Past or present neurological disorder (multiple sclerosis, brain tumour, epilepsy, stroke, traumatic brain injury); * Severe psychiatric disorder (schizophrenia, major depression, bipolar disorder); * Diabetes or hypertension without medical monitoring; * Alcoholism or drug addiction; * Any other condition expected to limit participation (e.g., low visual acuity).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Risk-Taking dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lucilab

    Montreal, Quebec, H2T 1A8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.